|
24 Jul 2020 |
Heron Therapeutics Receives Positive CHMP Opinion for ZYNRELEF™ (HTX-011) for the Management of Postoperative Pain
|
|
24 Jul 2020 |
Insmed Receives Positive CHMP Opinion for ARIKAYCE Liposomal 590 mg Nebuliser Dispersion for the Treatment of NTM Lung Infections Caused by MAC in Non-CF Patients with Limited Treatment Options
|
|
24 Jul 2020 |
Breztri Aerosphere approved in the US for the maintenance treatment of COPD
|
|
23 Jul 2020 |
Pipeline Therapeutics Initiates Phase 1/2a Clinical Trial of PIPE-505 in Sensorineural Hearing Loss
|
|
23 Jul 2020 |
Novartis announces Phase III study of Jakavi® in chronic graft-versus-host disease met primary and key secondary endpoints
|
|
23 Jul 2020 |
Pharmaxis Submits Investigational New Drug Application for the Treatment of Myelofibrosis
|
|
23 Jul 2020 |
Zydus receives approval from USFDA to initiate clinical trials of Desidustat in cancer patients receiving chemotherapy
|
|
22 Jul 2020 |
Grünenthal and Averitas Pharma Announce U.S. FDA Approval of QUTENZA® for the Treatment of Neuropathic Pain Associated with Diabetic Peripheral Neuropathy of the Feet
|
|
22 Jul 2020 |
Ascentage Pharma Announces First Patient Dosed in the Phase Ib Study of MDM2-p53 Inhibitor APG-115 as Single Agent and in Combinations for the Treatment of Hematologic Malignancies in China
|
|
22 Jul 2020 |
Astellas is Awarded Grant from the U.S. National Institutes of Health (NIH) to Fund Early Clinical Studies of ASP8062 to Investigate Potential Novel Therapeutic Approach to Address the Opioid Crisis
|
|
22 Jul 2020 |
Terns Pharmaceuticals Announces Initiation of Patient Dosing in the LIFT Study, a Phase 2a Clinical Trial of TERN-101 in Development for NASH
|
|
22 Jul 2020 |
RINVOQ™ (upadacitinib) Monotherapy Meets All Primary and Secondary Endpoints in Second Phase 3 Study for Atopic Dermatitis
|
|
21 Jul 2020 |
ACADIA Pharmaceuticals Announces Top-line Results from the Phase 3 CLARITY Study Evaluating Pimavanserin for the Adjunctive Treatment of Major Depressive Disorder
|
|
21 Jul 2020 |
Daiichi Sankyo Announces Phase 3 Study Results for Prasugrel Antiplatelet Agent in Thrombotic Stroke Patients
|
|
20 Jul 2020 |
BioXcel Therapeutics Announces Primary and Secondary Endpoints Met in Two Pivotal Phase 3 Trials of BXCL501 for the Acute Treatment of Agitation in Patients with Schizophrenia and Bipolar Disorder
|
|
20 Jul 2020 |
Belite Bio Announces Positive Results from Phase 1 Clinical Trials of LBS-008
|
|
20 Jul 2020 |
Amplyx Announces Positive Top-line Data in Phase 2 Clinical Trial of Novel Antifungal Fosmanogepix
|
|
20 Jul 2020 |
Exelixis Announces Initiation of CONTACT-03 Phase 3 Pivotal Trial of Cabozantinib in Combination With Atezolizumab in Previously Treated Metastatic Renal Cell Carcinoma
|
|
20 Jul 2020 |
Positive Phase 3 Study Results for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in People Ages 12 and Older With Cystic Fibrosis Who Have One Copy of the F508del Mutation and One Gating or Residual Function Mutation
|
|
20 Jul 2020 |
Orphazyme completes rolling submission of New Drug Application to U.S. FDA for arimoclomol for Niemann-Pick disease Type C
|
|
20 Jul 2020 |
Bergenbio Announces First Patient Dosed in Recurrent Glioblastoma Investigator Sponsored Phase I/II Study Assessing Selective AXL Inhibitor Bemcentinib
|
|
20 Jul 2020 |
Sanifit to start new clinical development program of SNF472 in End Stage Kidney Disease patients with Peripheral Artery Disease
|
|
16 Jul 2020 |
Kronos Bio and Gilead Sciences Enter Into Asset Purchase Agreement for Gilead's SYK Inhibitor Portfolio
|
|
16 Jul 2020 |
MC2 Therapeutics Announces Submission of Marketing Authorization Application in EU for Wynzora® Cream (50 µg/g calcipotriol and 0.5 mg/g betamethasone (as dipropionate))
|
|
16 Jul 2020 |
FDA Grants Priority Review to Merck’s New Drug Application for Vericiguat
|
